Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 3/2014

01.09.2014 | Original Article

Hairy Cell Leukemia: Clinicopathological and Immunophenotypic Study

verfasst von: Kaumudi Konkay, Megha S. Uppin, Shantveer G. Uppin, D. Raghunadha Rao, CH. Geetha, T. Roshni Paul

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Hairy cell leukemia (HCL) is a rare neoplasm of mature small B lymphoid cells with characteristic circumferential ‘hairy projections’ involving the peripheral blood, bone marrow and splenic red pulp. With the advent of immunophenotyping and newer treatment modalities, prolonged remission can be achieved after a definitive diagnosis. Due to the rarity of this condition and presence of only a few case series from India, this work was undertaken. The aim was to study the clinico-pathologic and immunophenotypic features of all cases diagnosed as hairy cell leukemia. The cases were retrieved from Hematopathology records, between 1991 and 2012. The complete clinical details, investigations, treatment and follow-up were obtained from Medical Oncology records. The peripheral blood picture, bone marrow cytology and trephine sections along with special stains were reviewed. There were 12 cases of HCL during the study period with a M:F ratio of 11:1. Of these, ten were diagnosed as classical HCL and two as variant HCL. The most common clinical manifestations were fever, easy fatigability and weakness. Splenomegaly was present in 81.8 % cases. Though all the patients showed some form of cytopenia, there were three (25 %) patients with leucocytosis. The smears from all patients showed atypical lymphoid cells with circumferential hairy projections. TRAP was positive in 9 patients (81.8 %). Immunophenotyping was done in six cases, four were confirmed as HCL and two were diagnosed as HCL-v. The patients treated with Cladribine generally had a good response. The characteristic morphology of the hairy cells; along with correlation with the clinical features, TRAP positivity and immunophenotyping by flow cytometry is essential for diagnosis. Treatment response with Cladribine is good and has prolonged remission rates.
Literatur
1.
Zurück zum Zitat Galani KS, Subramanian PG, Gadage VS et al (2012) Clinico-pathological profile of hairy cell leukemia: critical insights gained at a tertiary care cancer hospital. Indian J Pathol Microbiol 55:61–65PubMedCrossRef Galani KS, Subramanian PG, Gadage VS et al (2012) Clinico-pathological profile of hairy cell leukemia: critical insights gained at a tertiary care cancer hospital. Indian J Pathol Microbiol 55:61–65PubMedCrossRef
2.
Zurück zum Zitat Chatterjee T, Panigrahi I, Mahapatra M et al (2008) Hairy cell leukemia: clinical, pathological and ultrastructural findings in Asian–Indians. Indian J Cancer 45:41–44PubMedCrossRef Chatterjee T, Panigrahi I, Mahapatra M et al (2008) Hairy cell leukemia: clinical, pathological and ultrastructural findings in Asian–Indians. Indian J Cancer 45:41–44PubMedCrossRef
3.
Zurück zum Zitat Medhi K, Kumar L, Sharma A et al (2006) Hairy cell leukemia: experience at a Tertiary Cancer Centre in Northern India. Indian J Med Pediatr Oncol 27:8–14 Medhi K, Kumar L, Sharma A et al (2006) Hairy cell leukemia: experience at a Tertiary Cancer Centre in Northern India. Indian J Med Pediatr Oncol 27:8–14
4.
Zurück zum Zitat Goodman GR, Bethel KJ, Saven A (2003) Hairy cell leukemia: an update. Curr Opin Hematol 10:258–266PubMedCrossRef Goodman GR, Bethel KJ, Saven A (2003) Hairy cell leukemia: an update. Curr Opin Hematol 10:258–266PubMedCrossRef
5.
Zurück zum Zitat Bouroncle BA, Wiseman BK, Doan CA (1958) Leukemic reticuloendotheliosis. Blood 13:609–630PubMed Bouroncle BA, Wiseman BK, Doan CA (1958) Leukemic reticuloendotheliosis. Blood 13:609–630PubMed
6.
Zurück zum Zitat Schrek R, Donnelly WJ (1966) Hairy cells in blood in lymphoreticular neoplastic disease and flagellated cells of normal lymph nodes. Blood 27:199–211PubMed Schrek R, Donnelly WJ (1966) Hairy cells in blood in lymphoreticular neoplastic disease and flagellated cells of normal lymph nodes. Blood 27:199–211PubMed
7.
Zurück zum Zitat Foucar K, Falini B, Catovsky D, Stein H (2008) Hairy cell leukemia. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of hematopoietic and lymphoid tissues. IARC, Lyon, pp 188–193 Foucar K, Falini B, Catovsky D, Stein H (2008) Hairy cell leukemia. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of hematopoietic and lymphoid tissues. IARC, Lyon, pp 188–193
8.
Zurück zum Zitat Flandrin G, Collado S (1987) Is male predominance (4/1) in hairy cell leukaemia related to occupational exposure to ionizing radiation, benzene and other solvents? Br J Haematol 67:119–120PubMedCrossRef Flandrin G, Collado S (1987) Is male predominance (4/1) in hairy cell leukaemia related to occupational exposure to ionizing radiation, benzene and other solvents? Br J Haematol 67:119–120PubMedCrossRef
9.
Zurück zum Zitat Polliack A (2002) Hairy cell leukemia: biology, clinical diagnosis, unusual manifestations and associated disorders. Rev Clin Exp Hematol 6:366–388 discussion 449–450PubMedCrossRef Polliack A (2002) Hairy cell leukemia: biology, clinical diagnosis, unusual manifestations and associated disorders. Rev Clin Exp Hematol 6:366–388 discussion 449–450PubMedCrossRef
10.
Zurück zum Zitat Adley BP, Sun X, Shaw JM, Variakojis D (2003) Hairy cell leukemia with marked lymphocytosis. Arch Pathol Lab Med 12:253–254 Adley BP, Sun X, Shaw JM, Variakojis D (2003) Hairy cell leukemia with marked lymphocytosis. Arch Pathol Lab Med 12:253–254
11.
Zurück zum Zitat Yam LT, Janckila AJ, Li CY, Lam WK (1987) Cytochemistry of tartrate-resistant acid phosphatase: 15 years’ experience. Leukemia 1:285–288PubMed Yam LT, Janckila AJ, Li CY, Lam WK (1987) Cytochemistry of tartrate-resistant acid phosphatase: 15 years’ experience. Leukemia 1:285–288PubMed
12.
Zurück zum Zitat Wu ML, Kwaan HC, Goolsby CL (2000) Atypical hairy cell leukemia. Arch Pathol Lab Med 124:1710–1713PubMed Wu ML, Kwaan HC, Goolsby CL (2000) Atypical hairy cell leukemia. Arch Pathol Lab Med 124:1710–1713PubMed
13.
Zurück zum Zitat Sainati L, Matutes E, Mulligan S et al (1990) A variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients. Blood 76:157–162PubMed Sainati L, Matutes E, Mulligan S et al (1990) A variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients. Blood 76:157–162PubMed
14.
Zurück zum Zitat Blasinska-Morawiec M, Robak T, Krykowski E et al (1997) Hairy cell leukemia variant treated with 2-chlorodeoxyadenosine: a report of three cases. Leuk Lymphoma 25:381–385PubMed Blasinska-Morawiec M, Robak T, Krykowski E et al (1997) Hairy cell leukemia variant treated with 2-chlorodeoxyadenosine: a report of three cases. Leuk Lymphoma 25:381–385PubMed
15.
Zurück zum Zitat Robak T, Blasinska-Morawiec M, Blonski J et al (1999) 2-Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol 62:49–56PubMedCrossRef Robak T, Blasinska-Morawiec M, Blonski J et al (1999) 2-Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol 62:49–56PubMedCrossRef
Metadaten
Titel
Hairy Cell Leukemia: Clinicopathological and Immunophenotypic Study
verfasst von
Kaumudi Konkay
Megha S. Uppin
Shantveer G. Uppin
D. Raghunadha Rao
CH. Geetha
T. Roshni Paul
Publikationsdatum
01.09.2014
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 3/2014
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-013-0231-x

Weitere Artikel der Ausgabe 3/2014

Indian Journal of Hematology and Blood Transfusion 3/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.